Dioseve Secures JPY 1.45 Billion to Advance iPS Cell‑Based IVF Support, Adds TIME100 Scientist as Advisor
Funding round and NEDO Deep Tech Startup Support Program selection will support development and clinical adoption of DIOS‑101, an iPS cell‑derived co‑culture designed to reduce the burden of IVF treatment. TOKYO, June 16, 2026 /PRNewswire/ -- Dioseve Inc. ("Dioseve"), a Tokyo-based...
Funding round and NEDO Deep Tech Startup Support Program selection will support development and clinical adoption of DIOS‑101, an iPS cell‑derived co‑culture designed to reduce the burden of IVF treatment. TOKYO, June 16, 2026 /PRNewswire/ -- Dioseve Inc. ("Dioseve"), a Tokyo-based...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.